PCM
CHRS icon

Prelude Capital Management’s Coherus Oncology CHRS Stock Holding History

Prelude Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,000
Closed -$27K – 1571
2016
Q3 		$27K Buy
+1,000
New +$27.3K ﹤0.01% 1266

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Prelude Capital Management's CHRS Position: Q3 2022 in Review

Prelude Capital Management sold out of Coherus Oncology (CHRS) in Q3 2022, closing a stake of 10,436 shares — an estimated $76K sold.

Prelude Capital Management first reported a position in CHRS in Q4 2014 and held it in 20 quarters. The position peaked at $232K in Q3 2021. 174 funds tracked by Wall St. Rank hold CHRS as of Q3 2022.

  • Prelude Capital Management reported no remaining Coherus Oncology position as of Q3 2022 after selling out during the quarter.
  • Prelude Capital Management sold 10,436 Coherus Oncology shares in Q3 2022, an estimated $76K.
  • Prelude Capital Management first reported a position in Coherus Oncology in Q4 2014 and held it in 20 quarters.
  • Prelude Capital Management's Coherus Oncology position peaked at $232K in Q3 2021.
  • 174 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2022.

Based on Prelude Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.